Raleigh Capital Management’s Marvell Technology MRVL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.27K Hold
31
﹤0.01% 382
2026
Q1
$3.08K Buy
+31
New +$2.6K ﹤0.01% 475
2025
Q4
Sell
-398
Closed -$34.8K 560
2025
Q3
$33.4K Sell
398
-21
-5% -$1.55K 0.01% 287
2025
Q2
$32.5K Sell
419
-47
-10% -$2.93K 0.01% 297
2025
Q1
$28.7K Sell
466
-116
-20% -$11.3K 0.01% 298
2024
Q4
$64.3K Buy
582
+487
+513% +$45.2K 0.02% 289
2024
Q3
$6.85K Hold
95
﹤0.01% 654
2024
Q2
$6.64K Hold
95
﹤0.01% 638
2024
Q1
$6.73K Sell
95
-130
-58% -$8.9K ﹤0.01% 610
2023
Q4
$13.6K Sell
225
-401
-64% -$21.7K 0.01% 512
2023
Q3
$33.9K Buy
626
+527
+532% +$31.1K 0.02% 304
2023
Q2
$5.92K Buy
+99
New +$4.81K ﹤0.01% 608
2023
Q1
Sell
-46
Closed -$1.71K 878
2022
Q4
$1.71K Hold
46
﹤0.01% 696
2022
Q3
$2K Hold
46
﹤0.01% 668
2022
Q2
$2K Buy
+46
New +$2.61K ﹤0.01% 544

Other funds holding MRVL

Raleigh Capital Management's MRVL Position: Q2 2026 in Review

Raleigh Capital Management held its Marvell Technology (MRVL) position steady in Q2 2026 at 31 shares worth $9.27K. The position accounts for ﹤0.01% of the portfolio, ranked #382.

Raleigh Capital Management first reported a position in MRVL in Q2 2022 and has held it in 15 quarters since. The position peaked at $64.3K in Q4 2024. 2,203 funds tracked by Wall St. Rank hold MRVL as of Q2 2026.

  • Raleigh Capital Management held 31 shares of Marvell Technology worth $9.27K as of Q2 2026.
  • Raleigh Capital Management left its Marvell Technology share count unchanged in Q2 2026.
  • Marvell Technology made up ﹤0.01% of Raleigh Capital Management's portfolio in Q2 2026, its #382 holding.
  • Raleigh Capital Management first reported a position in Marvell Technology in Q2 2022 and has held it in 15 quarters since.
  • Raleigh Capital Management's Marvell Technology position peaked at $64.3K in Q4 2024.
  • 2,203 funds tracked by Wall St. Rank held Marvell Technology as of Q2 2026.

Based on Raleigh Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.